Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ARS Pharmaceuticals Inc

SPRY ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: STRONG BUY

Last Close

$5.35

▼ -2.82%

Market Cap $532.04M · Vol 537.39K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$532.04M

Small Cap

Div Yield

N/A

EPS Growth

-2.59%

YoY

RSI (14)

50.43

Momentum

Beta

1.03

vs Market

52W High

$13.93

61.59% below

52W Low

$4.98

7.43% above

Volume

537.39K

Avg 645.12K

P/B

10.12

Price-to-book

ROE

N/A

Return on equity

Free Float

75.40%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ARS Pharmaceuticals Inc (SPRY) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SPRY pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-14.26%

-9.93%

-32.62%

-41.47%

YTD

-54.08%

-60.37%

-22.91%

-79.44%

Financials & Valuation

TTM · Annual

Total Revenue	$84.28M
Net Income	$-171,298,000.00
Revenue Growth (YoY)	+114.15%
Gross Margin	75.77%
Operating Margin	-212.92%
Net Profit Margin	-203.25%
ROE	N/A
ROA · ROIC	-50.49% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	13.63
P/B	10.12
P/FCF	N/A
EPS Growth	-2.59%
Outstanding Shares	99.45M

Technical Indicators

50-Day SMA	$7.17
200-Day SMA	$8.68
RSI (14)	50.43
Beta	1.03
52-Week High	$13.93
52-Week Low	$4.98

Volume Today	537.39K
Avg Daily Volume (30D)	645.12K
Relative Volume	0.83x
Volatility (10D)	97.42
Volatility (30D)	81.06
Free Float	75.40%

Analyst Consensus

STRONG BUY

Current Price $5.35

Mean Target $27.25

52W Low$4.98 52W High$13.93

Current

Target

$4.98 $13.93

Current Analyst target

+409.35% upside potential · 4 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00FZQGXH2

ISINUS82835W1080

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -0.74% RVMD Revolution Medicines Inc +1.01% ONC BeOne Medicines AG -0.66% 068270.KS Celltrion Inc +0.88% ABVX Abivax SA +1.04%

Company Profile

ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.